Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJanuszewski, Andrzej S.en_US
dc.contributor.authorChen, Daviden_US
dc.contributor.authorScott, Russell S.en_US
dc.contributor.authorO'Connell, Rachel L.en_US
dc.contributor.authorAryal, Nanda R.en_US
dc.contributor.authorSullivan, David R.en_US
dc.contributor.authorWatts, Gerald F.en_US
dc.contributor.authorTaskinen, Marja-Riittaen_US
dc.contributor.authorBarter, Philip J.en_US
dc.contributor.authorBest, James D.en_US
dc.contributor.authorSimes, John R.en_US
dc.contributor.authorKeech, Anthony C.en_US
dc.contributor.authorJenkins, Alicia J.en_US
dc.identifier.citationJanuszewski, A. S., Chen, D., Scott, R. S., O'Connell, R. L., Aryal, N. R., Sullivan, D. R., Watts, G. F., Taskinen, M., Barter, P. J., Best, J. D., Simes, J. R., Keech, A. C. & Jenkins, A. J. (2021). Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 11(1), 18708-.
dc.description.abstractPeople with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p ≤ 0.01). Baseline LMW-F tertiles correlated with on-trial macrovascular and microvascular complications (trend p < 0.001) on univariate analyses only. Six weeks of fenofibrate increased LMW-F levels by 21% (p < 0.001). In conclusion, LMW-F levels correlate with many risk factors and chronic diabetes complications, and are increased with fenofibrate. LMW-F tertiles predict complications, but not independently of traditional risk factors.en_US
dc.relation.ispartofScientific Reportsen_US
dc.rights© 2021 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
dc.titleRelationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetesen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.description.versionPublished versionen_US
dc.description.acknowledgementThe FIELD study was designed by an independent management committee and was coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney. The FIELD study was supported by funding from Laboratoires Fournier SA, Dijon, France (part of Solvay Pharmaceuticals, then Abbott and Mylan), and the NHMRC of Australia, including a Clinical Centre for Research Excellence Grant in Clinical Science in Diabetes (JDB, AJJ, ACK) and NHMRC Program Grants and Fellowships (RJS, AKK, AJJ). AJJ is also a Sydney Medical School Foundation Fellow. We thank the National Heart Foundation, Australia, Diabetes Australia, Diabetes New Zealand, and the Finnish Diabetes Association for endorsing the study. The sponsors of the study had no role in the data collection or data analysis. The authors had full access to all the data in the study. The authors and study management committee had final responsibility for the decision to submit the article for publication.en_US
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
s41598-021-98064-y.pdf1.84 MBAdobe PDFView/Open

Page view(s)

Updated on May 19, 2022


Updated on May 19, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.